Tonix Pharmaceuticals to Participate in Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”
February 16, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth...
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies
February 13, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Immunocompromised Individuals, Including Organ Transplant Recipients, Are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes SARS-CoV-2 has Mutated to Evade the Formerly EUA-Approved...
Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company’s Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)
February 09, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Preclinical data demonstrate the efficacy of TNX‐801 vaccination against monkeypox virus challenge in an animal model Phase 1 trial with TNX-801 for the prevention of monkeypox and smallpox is...
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘PREVENTION’ Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs
February 06, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately Four Million in U.S. Suffer from Chronic Migraine Development of TNX-1900 Also Planned for Treatment of Episodic...
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference
February 03, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth...
Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.
February 02, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
The Acquired Portfolio of Infectious Disease Assets Includes a Class of Potential Broad Spectrum Oral Antiviral Agents, TNX-3900 with a Host-Directed Mechanism Tonix Plans to Develop the TNX-3900...
Tonix Pharmaceuticals Announces Research Agreement with University of Maryland, Baltimore, to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Heart Xenograft Transplantation in Animals
February 01, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Research Study to Assess the Role of TNX-1500 in the Prevention of Heart Xenograft Rejection Preclinical Xenotransplantation Studies are Expected to Support Regulatory Filings for TNX-1500 CHATHAM,...
Tonix Pharmaceuticals Announces Presentation of Clinical and Non-Clinical TNX-1900 Data at the Annual Headache Cooperative of the Pacific (HCOP) Winter Conference
January 31, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Preliminary Results from Human PET Study Show that Intranasal Application of a Radioisotope of Magnesium-Potentiated Oxytocin is Delivered to the Trigeminal Ganglia Preliminary Results on Human...
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 30, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has...
Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 2nd Wnt & β-catenin Targeted Drug Development Conference
January 26, 2023 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tom...